Jette A van Lint (J A Van Lint, Jette A Van Lint, Jette van Lint)

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 17

Top Topics

Top Venues

Expert opinion on drug safety

The Journal of rheumatology

Annals of the rheumatic diseases

This page only lists publications with an associated author ORCID identifier.

Publications

Janneke M Quik, Helen R Gosselt, Jette A van Lint, Leanne J Kosse, Peter M Ten Klooster, Harald E Vonkeman, Bartholomeus J F van den Bemt, Naomi T Jessurun
The burden of adverse drug reactions reported by patients in the Dutch ADR monitor: a proof of concept. Expert opinion on drug safety (2024)
Benthe H König, Helen R Gosselt, Jette A van Lint, Leanne J Kosse, Bartholomeus J F van den Bemt, Peter M Ten Klooster, Harald E Vonkeman, Naomi T Jessurun
Quantification of longitudinal patient-reported burden of adverse drug reactions attributed to the use of TNF-α inhibitors in inflammatory rheumatic diseases: an observational prospective cohort study. Expert opinion on drug safety (2024)
A Louters, M Van Oosterhout, L Burgemeister, Naomi T Jessurun, Jette A van Lint
Prosthetic infections following tocilizumab treatment in patients with rheumatoid arthritis. Rheumatology (Oxford, England) (2024)
Benthe H König, Helen R Gosselt, Jette A van Lint, Leanne J Kosse, Bart J F Ten Klooster, Peter M van den Bemt, Harald E Vonkeman, Naomi T Jessurun
Quantification of Longitudinal Patient-Reported Burden of Adverse Drug Reactions Attributed to the Use of TNF-α Inhibitors in inflammatory rheumatic diseases: an observational prospective cohort study. Expert opinion on drug safety (2024)
Kimberly Velthuis, Naomi T Jessurun, Thi D M Nguyen, Joep H G Scholl, Jurriaan R G Jansen, Jette A van Lint, Leanne J Kosse, Peter M Ten Klooster, Harald E Vonkeman
First-time adverse drug reactions, survival analysis, and the share of adverse drug reactions in treatment discontinuation in real-world rheumatoid arthritis patients: a comparison of first-time treatment with adalimumab and etanercept. Expert opinion on drug safety (2023)
Roba A Alloush, Jette A van Lint, Rob J van Marum, Walter W A J J Hermens, Naomi T Jessurun
Hospital registration of Adverse Drug Reactions in Electronic health records: importance and contribution to pharmacovigilance. Expert opinion on drug safety (2023)
Helen R Gosselt, Jette A van Lint, Leanne J Kosse, Phyllis I Spuls, Harald E Vonkeman, Sander W Tas, Frank Hoentjen, Michael T Nurmohamed, Bart J F van den Bemt, Martijn Bastiaan Adriaan van Doorn, Naomi T Jessurun
Sex differences in adverse drug reactions from adalimumab and etanercept in patients with inflammatory rheumatic diseases. Expert opinion on drug safety (2023)
Jette A van Lint, Marlieke Sonnenberg, Harald E Vonkeman, Bart J F van den Bemt, Eugene P van Puijenbroek, Naomi T Jessurun
Development of a Framework Structuring Themes in the Course of Adverse Drug Reactions from a Patient's Perspective. Drug safety (2023)
Jette A van Lint, Naomi T Jessurun, Sander W Tas, Harald E Vonkeman, Martijn B A van Doorn, Frank Hoentjen, Michael T Nurmohamed, Eugene P van Puijenbroek, Bart J F van den Bemt
Recurring Fatigue After Biologic Administration: Patient-Reported Data from the Dutch Biologic Monitor. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy (2023)
Kimberly Velthuis, Naomi T Jessurun, Thi D M Nguyen, Joep H G Scholl, Jurriaan R G Jansen, Jette A van Lint, Leanne J Kosse, Peter M Ten Klooster, Harald E Vonkeman
First-time adverse drug reactions, survival analysis, and the share of adverse drug reactions in treatment discontinuation in real-world rheumatoid arthritis patients: a comparison of first-time treatment with adalimumab and etanercept. Expert opinion on drug safety (2023)
Helen R Gosselt, Jette A van Lint, Leanne J Kosse, Phyllis I Spuls, Harald E Vonkeman, Sander W Tas, Frank Hoentjen, Michael T Nurmohamed, Bart J F van den Bemt, Martijn Bastiaan Adriaan van Doorn, Naomi T Jessurun
Sex differences in adverse drug reactions from Adalimumab and etanercept in patients with inflammatory rheumatic diseases. Expert opinion on drug safety (2023)
Kimberly Velthuis, Naomi T Jessurun, Thi D M Nguyen, Joep Scholl, Jurriaan R G Jansen, Jette A van Lint, Leanne J Kosse, Peter M Ten Klooster, Harald E Vonkeman
First-time adverse drug reactions, survival analysis, and the share of adverse drug reactions in treatment discontinuation in real-world rheumatoid arthritis patients: a comparison of first-time treatment with adalimumab and etanercept. Expert opinion on drug safety (2023)
Lieke H Roest, Leanne J Kosse, Jette A van Lint, Helen R Gosselt, Joep H G Scholl, Eugene P van Puijenbroek, Harald E Vonkeman, Sander W Tas, Michael T Nurmohamed, Bart J F van den Bemt, Naomi T Jessurun
Disease-specific ADRs of TNF-α inhibitors as reported by patients with inflammatory rheumatic diseases: a registry-based prospective multicenter cohort study. Expert opinion on drug safety (2022)
Jette A van Lint, Naomi T Jessurun, Sander W Tas, Bart J F van den Bemt, Michael T Nurmohamed, Martijn B A van Doorn, Phyllis I Spuls, Astrid M van Tubergen, Peter M Ten Klooster, Eugene P van Puijenbroek, Frank Hoentjen, Harald E Vonkeman
Gastrointestinal Adverse Drug Reaction Profile of Etanercept: Real-world Data From Patients and Healthcare Professionals. The Journal of rheumatology 48 (9) (2021)
Jette A van Lint, Naomi T Jessurun, Renske C F Hebing, Frank Hoentjen, Sander W Tas, Harald E Vonkeman, Martijn B A van Doorn, Annemieke Sobels, Phyllis I Spuls, Eugene P van Puijenbroek, Michael T Nurmohamed, Bartholomeus J F van den Bemt
Patient-Reported Burden of Adverse Drug Reactions Attributed to Biologics Used for Immune-Mediated Inflammatory Diseases. Drug safety 43 (9) (2021)
Jette A van Lint, Tom Bakker, Peter M Ten Klooster, Eugene P van Puijenbroek, Harald E Vonkeman, Naomi T Jessurun
Neuropsychiatric adverse drug reactions associated with low dose methotrexate in rheumatoid arthritis patients. Expert opinion on drug safety (2021)
Jette A van Lint, Florence P A M van Hunsel, Sander W Tas, Harald E Vonkeman, Frank Hoentjen, Martijn Bastiaan Adriaan van Doorn, Renske C F Hebing, Michael T Nurmohamed, Bart J F van den Bemt, Eugene P van Puijenbroek, Naomi T Jessurun
Hypoglycaemia following JAK inhibitor treatment in patients with diabetes. Annals of the rheumatic diseases 81 (4) (2021)